Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Vaccines
Intercell Update on Technology Partnerships: Intercell Outlicenses Group B Streptococcus Vaccine
January 7th, 2009
Intercell announced that the Company has transferred on an exclusive basis its pre-clinical Group B Streptococcus (GBS) vaccine program to Novartis. At the same time Intercell has kept and received co-exclusive rights for the development of therapeutic antibodies against Group B Streptococcus and has in-licensed additional rights on GBS antibodies from Novartis. The GBS vaccine program was part of the vaccine portfolio for which Intercell had granted license options to Novartis under a strategic partnership closed in 2007. This step will trigger a recognition of revenue from the upfront option fee received under this strategic partnership. Furthermore, the collaboration...
Source: Vaccine Weekly (2009-01-07)
|
